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Abstract
Background—Higher serum ferritin levels may be influenced by iron use and inflammation, and 
are associated with higher mortality in hemodialysis (HD) patients. We hypothesized that a major 
rise in serum ferritin is associated with a higher risk of mortality, irrespective of baseline serum 
ferritin in incident HD patients.
Methods—In a cohort of 93,979 incident HD patients between 2007 and 2011, we examined the 
association of change in serum ferritin from the baseline patient quarter (first 91 days from 
dialysis start) to the subsequent quarter with mortality. Multivariable adjustments were done for 
case-mix and markers of the malnutrition, and inflammation complex and intravenous iron dose. 
Change in serum ferritin was stratified into 5 groups: <−400, −400 to <−100, −100 to <100, 100 to 
<400, and ≥400 ng/mL/quarter.
Results—The median change in serum ferritin was 89 ng/mL/quarter (interquartile range −55 to 
266 ng/mL/quarter). Compared to stable serum ferritin (−100 to <100 ng/mL/quarter), a major rise 
(≥400 ng/mL/quarter) was associated with higher all-cause mortality (hazard ratio [95% CI] 1.07 
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[0.99–1.15], 1.17 [1.09–1.24], 1.26 [1.12–1.41], and 1.49 [1.27–1.76] according to baseline serum 
ferritin: <200, 200 to <500, 500 to <800, and ≥800 ng/mL in adjusted models, respectively. The 
mortality risk associated with a rise in serum ferritin was robust, irrespective of intravenous iron 
use.
Conclusions—During the first 6-months after HD initiation, a major rise in serum ferritin in 
those with a baseline ferritin ≥200 ng/mL and even a slight rise in serum ferritin in those with a 
baseline ferritin ≥800 ng/mL are associated with higher mortality.
Keywords
Ferritin; Transferrin saturation; Hemodialysis; Mortality
Introduction
Serum ferritin is a marker used to reflect body iron storage [1, 2] and to monitor iron therapy 
in chronic kidney disease patients [3, 4]. Ferritin levels are influenced by both endogenous 
and exogenous iron as well as inflammatory conditions such as chronic diseases, infection, 
and cancer [5–7]. An iron-mediated rise of ferritin stems from dietary iron absorption, 
macrophage recycling [5, 8], and oral or intravenous (IV) iron administration [9]. Under 
inflammatory conditions, a liver-derived acute phase protein hepcidin inhibits iron 
absorption from the bowel, and iron release from macrophages and hepatocytes, thus 
restricting iron utilization in the body thereby leading to an increase in ferritin [10].
Among US non-dialysis dependent chronic kidney disease stage 5 patients, mean ferritin 
levels are approximately 150–250 ng/mL [11]; however, the mean ferritin may be upwards 
of 400 ng/mL among maintenance dialysis patients, which is attributed mostly to the 
initiation of IV iron therapy [12, 13]. The mean ferritin levels have been on the rise in 
maintenance dialysis patients since 1990 [12, 13] to a mean ferritin in excess of 800 ng/mL, 
as of 2011 [14]. A study in incident hemodialysis (HD) patients showed that there was a 
sharp increase in the first year of HD, which was followed by a subsequent rise in ferritin 
over time on dialysis [15]. Although initial increases in ferritin may be attributed to the 
administration of IV iron, sustained higher levels in maintenance dialysis patients may be 
attributed to lowering of erythropoietin [14] or other unknown causes [15].
Higher ferritin levels ≥800 ng/mL may be detrimental to patient survival and has been found 
to be associated with higher mortality risk in dialysis patients after adjustment for iron 
supplementation, safety of iron administration, malnutrition, or inflammation [16–18]. 
However, no study has investigated the relationship of abrupt changes in ferritin with 
mortality in incident HD patients. Thus, we aimed to investigate the association between 
ferritin changes over time and mortality in an incident HD population. We hypothesized that 
a rapid rise in ferritin over the first 6 months upon transition to maintenance HD is 
associated with a higher risk of mortality, independent of IV iron administration. We also 
examined whether the change in ferritin across strata of higher versus lower dose of 
prescribed IV iron during the same period has a bearing on mortality.
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Materials and Methods
Study Cohort
We conducted analyses using administrative data from all incident HD patients receiving 
dialysis treatment in one of the out-patient dialysis facilities of a large dialysis organization 
(LDO) from January 1, 2007 to December 31, 2011. The construction of this cohort has 
previously been described elsewhere [19]. Patients’ follow-up time was divided into 
consecutive 91-day intervals (patient quarters) from the time of patients’ first dialysis 
treatment over the entire study period. Over the follow-up period, 208,820 subjects started 
dialysis treatment. After excluding patients aged <18 or >99 years old at initiation, those 
who received less than 60 days of total treatment and who were treated with a dialysis 
modality other than thrice-weekly HD over the duration of follow-up, 133,156 incident HD 
patients remained. Patients were further excluded for missing ferritin measurements during 
the first 6 months of transition to maintenance HD. Therefore, the final study population 
consisted of 93,979 incident HD patients (online suppl. Appendix Fig. S1; for all online 
suppl. material, see www.karger.com/doi/10.1159/000478735).
The study was approved by the Institutional Review Committees of the University of 
California Irvine, Los Angeles Biomedical Research Institute at Harbor-UCLA, and the 
University of Washington. Given the large sample size, anonymity of studied patients, and 
nonintrusive nature of research, the requirement for written consent was exempted.
Demographic and Clinical Measures
Information on race/ethnicity, primary insurance, vascular access type, and the presence of 
comorbidities at baseline were obtained from the LDO database. The following 16 
preexisting co-morbidities were considered: diabetes, hypertension, cystic kidney disease, 
autoimmune disease, dyslipidemia, chronic obstructive pulmonary disease, liver disease, 
atherosclerotic heart disease, other cardiac disease (pericarditis and cardiac arrhythmia), 
congestive heart disease, cerebrovascular disease, malignancy, thyroid disorders, human 
immunodeficiency virus, substance use, and alcohol abuse.
Laboratory Measures
Blood samples were drawn using standardized techniques in the LDO clinics and were 
transported to the LDO laboratory in Deland, Florida, typically within 24 h. Most laboratory 
values were measured monthly, including serum creatinine, albumin, hemoglobin, 
hematocrit, platelet, peripheral white blood cell, lymphocyte percentage, total iron binding 
capacity (TIBC), iron saturation (ISAT), calcium, phosphorus, bicarbonate, and alkaline 
phosphatase. Serum intact parathyroid hormone (iPTH) and ferritin levels were usually 
measured at least once during each calendar quarter. Most blood samples were collected 
before dialysis, except for post-dialysis blood urea nitrogen to calculate urea kinetics. The 
normalized protein catabolic rate (nPCR) was measured monthly as an indicator of daily 
protein intake. The dialysis dose was estimated by single pool Kt/V (spKt/V) using the urea 
kinetic model. To minimize measurement variability, all repeated measures for each patient 
during each patient quarter were averaged and summary estimates used in all models. The 
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quarterly averaged values during the first 91-days of dialysis (Q1) were used as baseline 
values to attenuate the effect of short-term variation in laboratory measurement.
Change in ferritin was calculated by subtracting the mean ferritin concentration during the 
first quarter (Q1) from the mean ferritin concentration during the second quarter (Q2). Δ 
ferritin was divided into 5 groups: less than −400, −400 to <−100, −100 to <100, 100 to 
<400, and ≥400 ng/mL/quarter.
Statistical Analysis
Patients’ baseline demographics, clinical characteristics, and laboratory measurements 
across change in ferritin groups were summarized as proportions, mean (±SD), or median 
(interquartile range) and compared using chi-square tests, analysis of variance, Kruskal-
Wallis tests, depending on data type. We used Cox proportional hazard models to evaluate 
the association of change in ferritin during the first 6 months of dialysis initiation (Δ ferritin) 
with all-cause mortality. We considered Δ ferritin of −100 to <100 ng/mL/quarter to be the 
reference group because it reflects a relatively stable change in ferritin over the first 6 
months of dialysis initiation. To test for effect modification of baseline ferritin, we 
performed stratified analyses by baseline ferritin (<200, 200 to <500, 500 to <800, and ≥800 
ng/mL).
For each analysis, three levels of multivariable adjustment were used: (1) a minimally 
adjusted model that included the main predictor (change in serum ferritin group) and the 
entry calendar quarter (time period of dialysis initiation); (2) a case-mix adjusted model that 
included covariates in the minimally adjusted model as well as age, sex, race/ethnicity 
(white, African-American, Hispanic, Asian, and others), primary insurance (Medicare, 
Medicaid, and others), access type (central venous catheter, arteriovenous fistula, 
arteriovenous graft, and others), spKt/V, and 16 aforementioned comorbidities; (3) a case-
mix and malnutrition-inflammation cachexia syndrome (MICS) adjusted model that 
included covariates in the case-mix model as well as iron and erythropoiesis-stimulating 
agent (ESA) dose, and 12 surrogates of nutritional and/or inflammatory status: serum 
creatinine, hemoglobin, albumin, peripheral white blood cell, lymphocyte percentage, TIBC, 
calcium, phosphorus, bicarbonate, iPTH, body mass index, and nPCR. All laboratory 
covariates, spKt/V, and access type were adjusted for the Δ of each value between 1st and 
2nd patient quarter as well as values from the 2nd patient quarter to account for the 
simultaneous change that may occur over time as well. The assumption of proportional 
hazards was assessed by log-log plots. Patients were followed after the 2nd patient quarter 
until death, transplantation, transfer to a non-affiliated clinic or end of the study period 
(December 31, 2011).
To account for the effect of IV iron use on the change in ferritin and mortality, the cohort 
was divided into IV iron use and no IV iron use groups over the first 6 months of dialysis. 
We used a singular referent group of stable levels of ferritin (Δ ferritin −100 to <100 ng/mL/
quarter) and baseline ferritin 200 to <500 ng/mL as the referent group.
We used the Spearman correlation to examine the relationship between change in ferritin 
and change in ISAT, and stratified among the change in ferritin groups. The comparison of 
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change in ISAT and other laboratory measurements across change in ferritin groups were 
compared using trend tests. To evaluate the effect of ISAT on the association between 
change in ferritin and mortality, patients were divided according to the level of change in 
ISAT.
In sensitivity analyses, 18 different combinations based on groups of change in ferritin and 
groups of baseline ferritin were used and compared to a singular referent group of stable 
ferritin (Δ ferritin −100 to <100 ng/mL/quarter) and baseline ferritin 200 to <500 ng/mL, 
based on Kidney Disease Improving Global Outcomes recommended guidelines. Due to 
extremely small sample sizes, combinations of the change in ferritin <−400 ng/mL/quarter 
group and baseline ferritin groups of <200 and 200–<500 ng/mL were not created.
To further examine the relationship between change in ferritin and mortality, we performed 
subgroup analyses and tested for interactions between Δ ferritin and covariates using Wald’s 
test.
Data on ferritin at the first and second patient quarters were available. Data on sex, race/
ethnicity, and comorbidities were missing for <0.5% of the cohort and not imputed. Other 
covariates including spKt/V, serum creatinine, hemoglobin, albumin, peripheral white blood 
cell, lymphocyte percentage, TIBC, calcium, phosphorus, bicarbonate, iPTH, body mass 
index, and nPCR were missing <5% and were imputed by using multiple imputation 
methods. All analyses were carried out using STATA MP version 13.1 (Stata Corp., College 
Station, TX, USA).
Results
Baseline Demographics According to Δ Ferritin
The analytic cohort comprised of 93,979 incident HD patients in whom the median Δ ferritin 
was 89 ng/mL (interquartile range −55 to 266 ng/mL). Online supplementary Appendix 
Figure S2 shows the distribution of change in ferritin over the first 6 months of HD in our 
cohort. Baseline characteristics of the total cohort and stratified by Δ ferritin groups are 
presented in Table 1. Patients who experienced a higher increase in ferritin level (≥400 
ng/mL/quarter) were more likely to be older, less likely to be African American, and had a 
higher prevalence of diabetes and other comorbidities (including hypertension, 
atherosclerotic heart disease, and dyslipidemia), had lower baseline ferritin, and higher 
baseline hemoglobin. Patients who experienced a greater decrease in ferritin level (<−400 
ng/mL/quarter) had a lower prevalence of diabetes and were more likely to be African 
American. In addition, these patients tended to have higher baseline ferritin and ISAT, and 
lower TIBC and hemoglobin levels. As expected, the highest quarterly averaged baseline 
monthly iron dose was observed in patients with Δ ferritin level ≥400 ng/mL/quarter.
Association of Ferritin Variations with Mortality
A total of 24,177 (25.7%) all-cause deaths were reported over follow-up. The crude 
mortality rate was 162 per 1,000 patient-years (95% CI 160–164). Across all strata of 
baseline ferritin, a major rise in ferritin ≥400 ng/mL/quarter over the first 6 months was 
associated with higher death risk during the subsequent 5 years compared to stable ferritin 
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(Δ ferritin −100 to <100 ng/mL/quarter; Fig. 1a–c). The highest mortality risk associated 
with a major rise in ferritin was observed among patients with baseline ferritin ≥800 ng/mL 
(hazard ratios [HR] 1.49 [95% CI 1.27–1.76]) after adjustment for case-mix and MICS 
covariates (Fig. 1c).
A drop in ferritin <−400 ng/mL/quarter in patients with baseline ferritin ≥800 ng/mL tended 
to be associated with lower mortality in the minimally adjusted model (HR 0.87 [95% CI 
0.76–0.98]; Fig. 1a). However, this association was attenuated after additional adjustment 
for case-mix covariates (HR 0.91 [95% CI 0.80–1.04]) and case-mix and MICS covariates 
(HR 0.98 [95% CI 0.86, 1.10]; Fig. 1b, c).
Similar trends were observed in sensitivity analyses using 18 exposure groups consisting of 
combinations of baseline and change in ferritin with referent group of stable ferritin (Δ 
ferritin −100 to <100 ng/mL/quarter) and baseline ferritin 200 to <500 ng/mL) (online suppl. 
Appendix Fig. S3). This is analysis also showed that a major rise in ferritin ≥400 ng/mL/
quarter was associated with higher mortality across increasing groups of baseline ferritin.
Effect Modifications by IV Iron Use, ISAT, Demographics, and Nutritional Parameters
The number of patients who never used IV iron during this period was relatively small 
(3,370 patients, or 3.6% of the cohort). Patients who never used IV iron had slightly lower 
levels of hemoglobin and iPTH, yet higher levels of serum ferritin and ISAT, compared to 
those using IV iron. We considered stable ferritin (Δ ferritin −100 to <100 ng/mL/quarter) 
and baseline ferritin 200 to <500 ng/mL as the referent groups in this analysis. In patients 
who never used IV iron during the first 6 months of HD, mortality HR for Δ ferritin ≥400 
ng/mL/quarter appeared to be relatively similar: 2.55 (95% CI 1.23–5.29), 2.02 (95% CI 
1.22–3.35), 1.67 (95% CI 0.74–3.74), and 2.04 (95% CI 1.41–2.97) according to baseline 
ferritin <200, 200 to <500, 500 to <800, and ≥800 ng/mL, respectively in case-mix + MICS 
adjusted models ( Fig. 2a). Conversely, in patients who were administered IV iron, the 
mortality risk associated with a rise in ferritin ≥400 ng/mL/quarter was incrementally higher 
across higher baseline ferritin strata (HR 1.05 [95% CI 0.98–1.12], HR 1.15 [95% CI 1.08–
1.22], HR 1.18 [95% CI 1.07–1.30], and HR 1.42 [95% CI 1.23–1.63] in baseline ferritin 
<200, 200 to <500, 500 to 800, and ≥800 ng/mL, respectively; p for trend <0.001) in case-
mix + MICS models (Fig. 2b). The mortality risk associated with the rise in ferritin ≥400 
ng/mL/quarter in patients with higher baseline ferritin ≥ 800 ng/mL appeared to be robust 
irrespective of IV iron use. To account for the association between the change in IV iron 
dose and mortality, 18 different combination groups were used as shown in Figure 3. The 
mortality risk associated with rise in ferritin ≥ 400 ng/mL/quarter appeared independent of 
IV iron dose change (increase or decrease) over 6 months (Fig. 3a, b).
The change in ISAT (Δ ISAT) over the first 6 months after HD initiation tended to increase 
across increasing Δ ferritin groups (online suppl. Appendix Table S1), and was positively 
correlated with Δ ferritin in Spearman correlation analysis (rho = 0.41, p < 0.001). The rise 
in ferritin ≥100 ng/mL/quarter was still associated with higher mortality (reference: change 
in ferritin −100 to <100 ng/mL/quarter and rise in ISAT), irrespective of the change in ISAT 
(Table 2).
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Subgroup analysis showed that higher rise in ferritin during the first 6 months of HD (≥ 400 
ng/mL/quarter) was associated with higher all-cause mortality compared to a stable ferritin 
(Δ ferritin −100 to <100 ng/mL/quarter) across a priori strata of demographics and 
nutritional parameters (Fig. 4).
Discussion
In a nationally representative contemporary cohort of 93,979 incident HD patients, we 
investigated the association between the change in ferritin over the first 6 months after HD 
initiation and mortality. We found that a major rise in ferritin ≥400 ng/mL/quarter was 
associated with higher mortality in patients with higher baseline ferritin compared to stable 
ferritin. These associations were still robust independent of the prescribed IV iron dose. 
Moreover, a rise in ferritin ≥100 ng/mL/quarter regardless of drop or rise in ISAT was 
associated with all-cause mortality.
In a prior study investigating the association of baseline ferritin with mortality in 
maintenance HD patients, ferritin <1200 ng/mL was associated with lower mortality risk 
after considering nutritional status and inflammation [18]. In another observational study, 
ferritin <800 ng/mL in incident dialysis patients was associated with lower mortality risk 
after iron supplementation [16]. Recently published guidelines recommended considering 
iron administration in dialysis patients with ferritin ≤500 ng/mL for safety [4, 20]. In the 6-
week extension study of Dialysis Patients’ Response to IV Iron with Elevated Ferritin, a rise 
in ferritin <1,200 ng/mL by IV iron was beneficial in maintaining hemoglobin levels and 
keeping ESA use down, but survival outcomes were not evaluated due to the short study 
period [21]. In our analysis, we found that a major rise in ferritin ≥400 ng/mL/quarter during 
the first 6-months after HD initiation was significantly associated with higher mortality risk 
even in patients with baseline ferritin 200 to <500 ng/mL at HD initiation. These findings 
suggest that a more cautious approach in selecting patients needing IV iron treatment may 
be appropriate.
Ferritin is not a direct surrogate of administered iron dose [14], but can be used as a valuable 
marker to reflect the total body iron storage in clinical practice. Elevated ferritin can reflect 
exogenous iron overload by iron treatment as well as inflammation from conditions 
including acute or chronic inflammatory disorders, malignant disease, and liver disease [22, 
23]. Serum ferritin is widely known as a nonspecific, acute phase reactant, which is affected 
by inflammatory pathways involving hepcidin upregulation and iron administration directly. 
Despite an increase of ferritin under inflammatory conditions, iron is sequestered in 
macrophage due to increased hepcidin [10] and is not available for erythropoiesis. 
Conversely, ESA therapy downregulates hepcidin synthesis and iron is rapidly mobilized out 
of the store, thus contributing to the decrease in serum ferritin [24]. Also, among incident 
dialysis patients, access type via a central venous catheter [25, 26] or malnutrition [6] may 
also lead to an inflammatory state in these patients. Previous studies have demonstrated 
higher serum ferritin levels among malnourished dialysis patients, and it is also a marker of 
morbidity, including infection, and mortality in dialysis patients [27]. In addition, HD 
treatment is associated with higher inflammatory biomarkers, leading to oxidative stress and 
inflammation [28–30]. It is difficult to differentiate what causes ferritin to rise in clinical 
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practice because inflammatory status as well as iron treatment might occur simultaneously 
in dialysis patients. Therefore, higher baseline serum ferritin and a major rise of ferritin with 
iron or without iron therapy may be observed due to various factors related to the 
inflammatory and malnutrition processes, which are also associated with higher mortality. 
Our findings have shown that even in patients without IV iron treatment, a major rise in 
ferritin was associated with a higher mortality risk compared to stable ferritin even after 
adjusting for dialysis access type and nutrition and inflammatory covariates. This finding 
suggests that the association between a steep rise in ferritin and high mortality are robust and 
independent of markers of malnutrition and inflammation, and IV iron use. However, there 
may be additional unknown mechanisms that contribute to the rise in serum ferritin, as well 
as other inflammatory makers not captured by covariates available in our data. Thus, 
additional studies are needed to further examine mechanistically the causes of a rise in 
serum ferritin independent of IV iron use, and the relationship of this rise with mortality in 
dialysis patients.
ISAT, which is the ratio of serum iron and TIBC, is one of the markers used to represent 
functional iron deficiency or overloading. Previous studies showed the association between 
low ISAT (less than 20–24%) and higher mortality [31, 32], and between ISAT 35–50% and 
lower mortality with time-varying analyses in maintenance HD patients [18]. In our incident 
HD patients, we found that the rise in both ferritin and ISAT over the first 6 months was 
associated with high mortality as expected; however, we also found that a rise in ferritin with 
a drop in ISAT was also associated with higher mortality. Therefore, the rise or drop in ISAT 
over the first 6 months did not show independent associations with mortality across strata of 
ferritin change. These findings suggest that rise in ferritin may be a more potent predictor of 
mortality rather than the change in ISAT during the first 6 months of HD initiation. Even 
though it is unknown as to why the change in ferritin is associated more with mortality than 
the change in ISAT, it is suggested that ISAT is an indirect marker affected by serum iron 
and TIBC. Serum iron tends to be overestimated after IV iron administration [18, 33, 34], 
and TIBC, which is a negative acute phase reactant, is influenced by inflammatory 
conditions [32].
The strengths of this study included the size and contemporary nature of the cohort, the 
evaluation of the association between all-cause mortality and the change in ferritin as early 
as 6 months after maintenance HD initiation, and the adjustment for numerous covariates 
related to malnutrition and inflammation. However, our study also has several limitations. 
First, direct inflammatory markers such as C-reactive protein and interleukin-6 were not 
available in our data. Although we adjusted for several potential inflammatory markers 
including albumin and TIBC as negative acute phase reactants as well as WBC as a positive 
acute phase reactant, residual confounding with inflammatory status may exist. This residual 
confounding may also explain the lack of better survival observed in patients with decreased 
serum ferritin after adjustment for malnutrition and inflammation markers. Second, a 
relatively small proportion of patients never received IV iron over 6 months after HD 
initiation (3.6%). Therefore, we were only able to evaluate the association of change in 
ferritin with mortality, independent of IV iron administration in this small stratum. However, 
to protect dialysis patients from potential iron deficiency, clinicians prescribe iron to most 
incident HD patients. After changes in dialysis reimbursement bundling for IV drugs in 
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2011, IV iron treatment increased in dialysis patients [14, 35]. Considering the prescription 
rates and policies for IV iron, 3.6% patients who were included in the no IV iron treatment 
analysis may not be such a small number.
In conclusion, in a large HD cohort study we found that the rapid rise in ferritin ≥400 ng/mL 
over the first 6 months upon transition to HD is associated with higher mortality, in 
particular in patients with higher baseline ferritin. These associations persisted, independent 
of changes in prescribed dose of IV iron and use of IV iron over the same period. The rise in 
ferritin ≥400 ng/mL/quarter is also associated with higher mortality regardless of the change 
in ISAT. Further studies investigating the underlying pathophysiological mechanisms 
between the relationship of increasing ferritin, administration of IV iron, and mortality may 
be warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
HRs (95% CIs) of all-cause mortality associated with change in serum ferritin over the first 
6 months after maintenance HD initiation across 4 baseline serum ferritin groups in 93,979 
incident HD patients. The models were adjusted (a) minimally with entry calendar quarter, 
additionally adjusted for (b) case-mix: age, sex, race/ethnicity, diabetes, insurance, dialysis 
access types, and dialysis dose Kt/V and comorbidities including hypertension, cystic kidney 
disease, autoimmune disease, dyslipidemia, chronic obstructive pulmonary disease, liver 
disease, atherosclerotic heart disease, other cardiac disease (pericarditis and cardiac 
arrhythmia), congestive heart disease, cerebrovascular disease, malignancy, thyroid 
disorders, human immunodeficiency virus, substance use and alcohol abuse); and 
additionally adjusted for (c) case-mix and MICS variables: case-mix variables plus serum 
creatinine, hemoglobin, albumin, peripheral white blood cell, lymphocyte percentage, total 
iron binding capacity, calcium, phosphorus, bicarbonate, iPTH, body mass index, 
normalized protein catabolic rate, iron dose, and ESA dose.
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Fig. 2. 
Case-mix and MICS-adjusted HRs (95% CIs) of all-cause mortality across 18 different 
combinations based on change in serum ferritin and baseline serum ferritin (a ) in the no IV 
iron use group (n = 3,354) and (b ) in the IV iron use group (n = 90,290). Reference group 
was stable serum ferritin (−100 to <100 ng/mL/quarter) and baseline serum ferritin 200 to 
<500 ng/mL.
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Fig. 3. 
HRs (95% CIs) of all-cause mortality across the 18 different combinations based on change 
in serum ferritin and baseline serum ferritin with (a ) drop in IV iron use group (n = 50,808) 
and (b) rise in IV iron use group (n = 36,533) in case-mix and MICS adjusted models. 
Reference group was stable change in serum ferritin (−100 to <100 ng/mL/quarter) and 
baseline serum ferritin 200 to <500 ng/mL.
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Fig. 4. 
Case-mix and MICS-adjusted HRs (95% CIs) of all-cause mortality associated with increase 
of change in serum ferritin ≥400 ng/mL/quarter across subgroups of age (<65, ≥65 year-old), 
sex (female, male), race (white, African American), diabetes, CHF, serum albumin (<3.8, 
≥3.8 g/dL), hemoglobin (<10, ≥10 g/dL), TIBC (<200, ≥200 mg/dL), nPCR (<1.0, ≥1.0 
g/kg/day), and BMI (<25, ≥25 kg/m 2). AfAm, African American; BMI, body mass index; 
CHF, congestive heart failure; HGB, hemoglobin; nPCR, normalized protein catabolic rate; 
TIBC, total iron binding capacity.
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